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Abstract
Chronic heart failure (CHF) was characterized by the failure of enough blood supply
from the heart to meet the body’s metabolic demands, and the prevalence of CHF
continuously increases  globally.  The personalized diagnosis  of  Traditional  Chinese
Medicine (TCM) classifies CHF into several different syndrome types, and integrating
Western and TCM to treat CHF has proved a validated therapeutic approach. Over the
last few years, there has been a rapidly growing number of metabolomics applications
aimed at finding biomarkers that could assist diagnosis, provide therapy guidance, and
evaluate response to therapy for individualized intervention of CHF. Thus,  in this
review, particular attention will be paid to the past successes in applications of state-of-
the-art  technology on  metabolomics  to  contribute  to  biomarker  discovery  in  CHF
research.
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1. Introduction
Chronic heart failure (CHF), a progressive clinical syndrome characterized by the inability of
the heart to adequately pump blood to meet metabolic demands of the body, represents the
final common ground of pathogenesis wherein various causes of heart damage converge [1].
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Despite a substantial improvement in the survival rate after the onset of CHF due to increasing
use of pharmacological interventions, mortality of patients suffering from CHF remains high.
Since it has been well recognized that the incidence and prevalence of CHF are expected to
further increase with the aging of the population, better strategy for the prevention and
treatment of CHF patients is still needed.
1.1. Epidemiology of CHF
CHF, in recent years, has been a major cause of morbidity and mortality in the general
population [2]. Both the increasing age of the population and success in the treatment of
patients with acute myocardial infarction raise the prevalence and thus the economic expen-
ditures of chronic heart failure [3]. Heart failure is not only a common, costly, disabling, and
potentially fatal condition but also the leading cause of hospitalization in people older than 65
[4]. In developing countries, 2–3% of the population suffers from heart failure, but in people
from 70 to 80 years old, it occurs in 20–30% [5]. In developed countries, around 2% of adults
suffer from heart failure, but in people older than 65, this increases to 6–10% [6].
1.2. Personalized intervention of CHF based on Traditional Chinese Medicine (TCM)
syndrome
With progress being made in bioinformatics and medical science, the view on health and
disease in Western life sciences has shifted from standard protocol-based disease manage-
ment to personalized medicine [7]. Based on personalized health and systematically diag-
nostic principles, Traditional Chinese Medicine (TCM) has proved effective to restore the
self-regulatory ability of the human system by thousands of years in clinic. And using inte-
grating TCM and Western medicine to treat CHF has been reported to enhance heart func-
tion and reduce related clinical symptoms, including expiratory dyspnea and chronic
fatigue, and subsequently improve echocardiographic measures, 6-min walking distance
test, and patients’ quality of life [8]. TCM physicians also pay more attention to the overall
maladjustments of functional status called “syndrome type” [9]. It is not simply an assem-
blage of diseases’ signs and symptoms but also a functional status caused by the reaction to
or interaction with environmental changes and pathogenic factors [10]. In other words, the
essence of TCM “syndrome type” is disturbance in biological metabolism networks, the
changes in concentration and relative proportions of metabolomic biomarkers resulting
from the imbalance of the human system. For example, yin deficiency syndrome of CHF
patients is described as low fever, night sweats, afternoon zygomaticus red, dysphoria (fe-
ver) in chest palms soles, dry mouth and throat, red tongue with little coating, and thready
rapid pulse according to the Clinical Terminology of Traditional Chinese Medical Diagnosis
and Treatment—Syndromes, and Yang deficiency syndrome of CHF is a cluster of symp-
toms including an aversion to coldness, dispirited feelings and lack of motivation, diarrhea
before dawn, shortness of breath, frequent urination, edema, and liability to catch cold.
Therefore, TCM syndrome, also defined as TCM pattern, is the essence of diagnosis and
treatment in TCM.
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2. Bringing metabolomics into the forefront of CHF research
The metabolome is the final downstream product of transcription and translation and is
thus closest to the phenotype [11]. Dynamics of primary metabolism operate in timescales of
seconds. These two characteristics allow the metabolome to be a sensitive and rapid meas-
ure of the system phenotype. Metabolomics were first defined in 1998 [12, 13]. Progress has
been made in methodological technologies that have lead to the discovery of metabolomic
biomarkers and greater knowledge regarding disease mechanism from that time. From the
1960s, applications of mass spectrometry (MS) [14] and nuclear magnetic resonance spectro-
scopy [15, 16] drove the first holistic studies of mammalian biofluids to be conducted. In the
past years, the development of technology has given impetus to metabolomics to its current
status. More than 13,000 studies searched in PubMed Database have proved metabolomics a
routinely applied tool nowadays. However, metabolomics is still the younger and smaller
sibling of proteomics, transcriptomics, and genomics. Metabolite profiles can provide a fin-
gerprint of metabolic changes that characterize the mechanism of CHF, a progressive clinical
syndrome, and also highlight the potential of metabolomic analysis in the evaluation of dis-
ease condition.
Metabolomics, as an important component of systematical biology, can be used to perform
dynamic studies on noninjured tissues and organs in vivo and in vitro using noninvasive
approaches under nearly physiological conditions. Therefore, metabolomic detection and
analysis of biological samples may contribute to understand the biochemical changes associ-
ated with the progression of diseases. And identification of disease-associated metabolic
biomarkers could allow early diagnosis of disease and establishment of predictive diagnostic
systems. It is reported that metabolomics gives itself unparalleled advantage to the most
common cardiovascular condition encountered in clinical practices, heart failure [17]. Metab-
olomics has also showed significant potential in TCM studies in recent years. And several
studies [18, 19] combining metabolomic techniques and TCM syndrome types have demon-
strated fingerprints of metabolic changes that characterize Western Medicine-diagnosed
diseases, which highlighted the potential of metabolomics in the evaluation of disease
condition and TCM-guided personalized treatment.
2.1. General procedures in which metabolomics can be used for diagnosis and biomarker
discovery
Metabolomics operates with a workflow [20, 21] starting from a biological question and
experiment, proceeding through sample collection and preparation, analytical experiment(s)
to acquire data, data preprocessing and analysis followed by biological interpretation. The
metabolomics experimental workflow involves the design of biological and analytical experi-
ments, sample preparation, data acquisition, data preprocessing and analysis and data
interpretation. This workflow leads to biological interpretation and reasoning, as shown in
Figure 1.
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1) Biological Experiment
(Design of experiment; Sample collection)
2) Analytical Experiment
(Sample preparation; Data acquisition)
3) Data Integration
(Data pre-processing;Data analysis;Integration with metadata)
4) Analysis and metabolite identification
5) Biological Interpretation
(Metabolomic biomarkers;biological mechanism)
Figure 1. The general workflow of metabolomic experiment.
Specifically, analytes in a metabolomic sample comprise a highly complex mixture. Mass
spectrometry (MS) is used to identify and to quantify metabolites after optional separation by
liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry
(GC-MS), nuclear magnetic resonance (NMR) spectroscopy, and capillary electrophoresis (CE).
The raw data usually consist of measurements performed on subjects under various condi-
tions. These measurements may be digitized spectra, or a list of metabolite levels. The software,
called XCMS, is one of the most widely cited mass spectrometry-based metabolomics software
programs in scientific literature. Prior to multivariate data analysis, statistical analyses are
performed using SIMCA-P+12 software (Umetrics, Umea, Sweden) as variables and then
mean-centered and pareto-scaled. Principal component analysis (PCA) and orthogonal partial
least-squares discriminant analysis (OPLS-DA) are commonly used for the processed data.
Score and loading plots are calculated to demonstrate discriminatory metabolites for each
group; clustering of samples with similar metabolic fingerprints can be detected. This cluster-
ing can elucidate patterns and assist in the determination of disease biomarkers.
Two generalized experimental strategies are applied, metabolic profiling (or metabolomics)
and metabolite-targeted analysis. Metabolic profiling allows comprehensive phenotyping of
genetically or environmentally modified systems. The study is devised so as to acquire data
on a large scale of metabolites (100–1000s) followed by interrogation of these data to figure out
biological differences. The design of metabolomic experiments is of great importance here as
it becomes easier to introduce confounding factors that are not recognized during data analysis
and which can falsify biological conclusions [22].
2.2. Advances in metabolomics techniques and related statistical methods
Without knowing which metabolites are of specific biological interest, powerful analytical
methods are used to illustrate thousands of metabolites reproducibly in a single sample.
Relative alterations in metabolite concentrations are researched, and at this stage, the absolute
concentrations of metabolites are not generally identified. With the goal to figure out all
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metabolites, this is currently not technologically realized. A platform of sample preparation
and analytical methods is applied to acquire good coverage of identified metabolites (e.g., give
reference to the Husermet project where LC-MS, GC-MS, and NMR spectroscopy have all been
used; www.husermet.org). The application of univariate and multivariate analysis tools [23–
25] was performed to process data. These discovery-phase researches and hypothesis-
generating or inductive studies [26], sometimes by the non-cognoscenti as a “fishing expedi-
tion,” aim to detect new biological and metabolomic markers. Moreover, another strategy,
driven from known biology where a limited number of metabolites (generally less than 20) are
known to be biologically relevant before the biological experiment, is conducted, and accurate
quantification of distinguished metabolites is analyzed in a designed approach. Under the
remit of traditional analytical chemistry and biochemical assays commonly found in clinical
laboratories, this strategy has been applied for decades.
3. Biomarkers and metabolomics studies on CHF
In studies of human beings, metabolomics has been applied to define biomarkers related to
prognosis or diagnosis of a disease or drug toxicity/efficacy, and it is hoped to provide greater
pathophysiological understanding of disease or therapeutic toxicity/efficacy by these studies
[27]. Coupling bioinformatics and biostatistics with metabolomic technology platforms
permits the identification and quantification of molecules to characterize the whole organism’s
response to diseases [28]. Studies have demonstrated that metabolomics lends itself ideally to
the most common cardiovascular condition encountered in clinical practices, heart failure [29].
Serum metabolites collected from 52 patients developed with CHF and 57 controls were
analyzed and 38 peaks illustrated significant differences between patients and controls. As the
current gold-standard biomarker brain natriuretic peptide (BNP), two metabolites of pseu-
douridine including a modified nucleotide present in tRNA and rRNA, a marker of cell
turnover, and the tricarboxylic acid cycle intermediate 2-oxoglutarate were at least as diag-
nostic metabolic biomarkers of heart failure [30]. Moreover, 2-hydroxy, 2-methylpropanoic
acid, erythritol, and 2, 4, 6-trihydroxypyrimidine were also good discriminators for cases and
controls observed. We identified metabolites from early experiments, also biomarkers in the
future, and will need to lay a foundation for larger, prospective, externally validated researches
in clinical studies. Our study used to apply a metabolomics approach to plasma obtained
directly from patients in order to assess its accuracy and reliability in diagnosing CHF, which
showed better performance in terms of both specificity and sensitivity. It should be noted that
the heart is known to consume a diverse set of fuel substrates, including lactate, glucose, amino
acids, ketones, and particularly free fatty acids (FFAs). The metabolites include energy
metabolism-related molecules, lipid/protein complexes, and amino acids. Plasma samples
from 39 CHF patients and 15 controls were analyzed by NMR spectroscopy. After processing
the data, PCA and OPLS-DA were performed. The statistical model revealed good explained
variance and predictability, and the diagnostic performance assessed by leave-one-out analysis
exhibited 92.31% sensitivity and 86.67% specificity. The OPLS-DA score plots of spectra
revealed good separation between case and control on the level of metabolites, and multiple
Application of Metabolomics for the Diagnosis and Traditional Chinese Medicine Syndrome...
http://dx.doi.org/10.5772/66209
175
biochemical changes indicated hyperlipidemia, alteration of energy metabolism, and other
potential biological mechanisms underlying CHF. It was concluded that the NMR-based
metabolomics approach demonstrated good performance to identify diagnostic plasma
markers and provided new insights into metabolic process related to CHF.
It has become well recognized that alteration in energy metabolites is of great importance in
chronic heart failure in recent years. Impairment in extraction of a wide range of metabolites,
probably pointing to severe energy deficiency, always leads to cardiac dysfunction in CHF
patients. Moreover, higher level of lactate and decreased glucose in plasma metabolites seem
to aggravate the impairment of energetic pathway in patients with CHF. A few metabolites
relevant only in distinguishing CHF patients from healthy controls could be associated with
prolonged exertion. Therefore, we observed increased lactate during anaerobic exercise. When
stores of glucose are low and concentration of oxaloacetate has been exhausted, acetone is
generated accordingly. Furthermore, alanine is expected to rise resulting from gluconeogenesis
when lactate is produced [31]. A rise in creatine, phosphorylated to phosphocreatine in muscle,
may indicate a physiological state of energy depletion. Besides, glycolate is of great importance
in energy generation by mitochondria. Pyruvate stem from glycolysis is diverted away from
the pyruvate dehydrogenase and toward the lactate dehydrogenase reaction, which contrib-
utes to the increase in lactate. A rise in acetyl-CoA may facilitate the inhibition of pyruvate
dehydrogenase, which continues to be stemmed from fatty acid oxidation; however, it
accumulates on the account of lowered trichloroacetic acid (TCA) cycle flux. Stress on energy
metabolism can also affect metabolic area in CHF patients. 3-Hydroxybutyrate, 2-hydroxyi-
sobutyrate, and 3-methyladipate had proved significant in glucose and lipid metabolism by
Lin’s study [32]. Glycoprotein and carnitine are reported in oxidative metabolism in mito-
chondrial and hypoxemic stress [33]. These results suggested oxidative fuel decrease and a
greater reliance on anaerobic metabolism of glucose for energy production in the plasma of
CHF patients.
In CHF patients, increased low-density lipoprotein (LDL) and decreased high-density
lipoprotein (HDL) were observed to be relative to lipolysis as a backup mechanism for energy
generation. Previous proteomic analysis of left-atrial cardiomyocyte and tissue samples from
the congestive heart failure model also found significant alterations in apolipoprotein levels
[34]. As apolipoproteins play a significant role in lipid metabolism, the alterations in apolipo-
protein concentrations indicate that lipid metabolic dysregulation may be relative to CHD.
Other studies have shown a close relationship between CHF and lipid regulation, which may
account for the high comorbidity between metabolic syndrome and CHF [35]. Along these
lines, previous study examining FFA extraction in myocardial ischemia patients also has found
decreased FFA extraction and oxidation [36]. Choline and its derivatives represent important
constituents in phospholipid metabolism of cell membranes and have been previously
identified as markers of cellular proliferation. To summarize, CHF patients have limited
myocardial metabolic reserve and flexibility, which verify a preliminary hypothesis of
association between lipid metabolic disorder and CHF.
The change of the TCA cycle may also be a metabolic marker in CHF patients. Impaired TCA
cycle flux, derived from the catabolism of glucose and amino acids, appears to occur in part
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through limiting levels of anaplerotic substrates [37]. The fall in glutamate/glutamine uptake
was observed in CHF patients because they would normally be transfinite to form the
anaplerotic substrate α-ketoglutarate. An increase in alanine release was also noted. The net
production of alanine likely occurs via transamination of pyruvate, with glutamate as the
nitrogen donor in the alanine transaminase reaction. In this period, this metabolic signature is
consistent with impaired glucose oxidation resulted in the diversion of pyruvate away from
the TCA cycle and into alanine transaminase reactions. Some scholars hypothesize that CHF
activates proteolysis of skeletal muscle and enhances branched amino acid oxidation, as was
described in inflammatory states [38]. Besides that, increased proline had been reported to play
a role in coronary atherosclerosis diseases [39]. In view of these studies, the heart’s ability to
maintain homeostasis via glycogeolysis, neoglucogenesis and ketogenesis is compromised
with CHF, as well as altering the amino acids.
4. Diagnostic power of metabolomics in TCM syndromes of CHF
Despite advances in the drug treatment strategy for CHF, the number of deaths resulting from
this condition continues to rise [40]. TCM pays special attention to the integrity and holism of
the human body and its interrelationship with nature. Based on different symptoms and signs,
TCM adheres to the basic principle to treat the same disease by different methods and different
diseases by one method and emphasizes personalized treatment, which truly indicates the
essence of TCM intervention [41]. Therefore, treatment based on syndrome differentiation is
the core of TCM therapy or CHF. From the perspective of TCM, CHF may occur in all
differentiation types, including qi deficiency and blood stasis, yang deficiency and water
retention, yin deficiency, and so on. Many Chinese herbs have demonstrated safety and efficacy
in the management of chronic heart failure in either animal models or humans [42, 43]. In
addition, modern biologic research has entered an era of integrating various research tech-
nologies and methods to tackle difficult biological problems at biomolecular level as a whole,
which is exemplified by studies in the new scientific fields of metabolomics. It is therefore
crucial to investigate the potential correlation between TCM syndrome type and metabolites
to develop novel therapeutic approaches for better treatment of CHF.
4.1. Qi deficiency and blood stasis syndrome
Based on TCM, we classified CHF patients into several syndromes. We investigated plasma
metabolites of CHF patients with qi deficiency and blood stasis syndrome to illuminate new
approaches to the diagnosis and identify metabolic signatures of TCM syndromes in CHF.
Combining plasma metabolomics with TCM syndrome-type diagnosis showed the distin-
guished metabolites of CHF patients with qi deficiency and blood stasis syndrome, including
energy metabolites (glucose, lactate, and glycoprotein), lipid/protein complexes [HDL, LDL/
very low-density lipoprotein (VLDL)], and amino acids (alanine, glutamate, valine, glycine,
proline, and carnitine). Therefore, this metabolomic method may demonstrate potential in
understanding of TCM syndromes of CHF. It is indisputable that there are limitations to each
study with any other new diagnostic approaches. Here, the effects of other confounding factors
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on the metabolic profiles, though, can be analyzed by further studies with large cohort required
to validate this method. For plasma samples representing the effects of metabolism in different
organs, it is also difficult to assign a metabolic fingerprint to specific metabolic processes [44].
However, it should be noted that the altered metabolites are reflected in CHF patients with
certain TCM syndrome, which can be harnessed as markers of diseases.
Qi deficiency and blood stasis syndrome, as a major syndrome among CHF patients, show a
distinct signature of altered metabolism, which includes increased level of lactate, gly-protein,
low-density lipoprotein (LDL)/very low-density lipoprotein (VLDL), and lower levels of
glucose, valine, proline, alanine, and carnitine. And glycoprotein is closely associated with the
physiology and pathology of cells’ growth and can affect human metabolic energy supply and
cellular immunity [45]. Furthermore, increased level of LDL and VLDL was observed in CHF
patients with qi deficiency and blood stasis syndrome, which were the most prominent factors
differentiating from controls. This metabolomics profile could be associated with lipolysis as
a backup mechanism for energy utilization, for apolipoproteins are of great weight in lipid
metabolism. Meanwhile, the plasma levels of well-known essential and nonessential amino
acids (such as alanine and valine) decreased in the CHF patients with qi deficiency and blood
stasis syndrome, breaking the internal equilibrium of the body gradually. This is in line with
Yan’s research; a metabolomics study on the rat model of myocardial ischemia with this
syndrome showed that increased inositol and decreased valine, glycine, and serine were
closely associated with energy metabolism and oxidative stress response [46]. Besides that,
carnitine, an important substance involved in fat metabolism and energy supply, reduced
dramatically in these patients. Studies have confirmed that L-carnitine can increase the uptake
of free fatty acids (FAA), which will make use of glucose as oxidative fuel in certain circum-
stances [47]. If carnitine was insufficient, the oxidation process in mitochondria will be affected,
which leads to the imbalance of cell metabolism and heart diseases. Tricarboxylic acid cycle,
carbohydrates, proteins, and fats would involve in the above metabolic processes, indicating
a complicated metabolic disorder in CHF patients with qi deficiency and blood stasis syn-
drome. Therefore, this metabolomic method may demonstrate potential in understanding of
qi deficiency and blood stasis syndrome of CHF. It is indisputable that there are limitations to
each new diagnostic approach. The effects of other confounding factors on the metabolic
profiles, though, can be analyzed by further studies with large cohort required to validate this
method [47]. For plasma samples representing the effects of metabolism in different organs, it
is also difficult to assign a metabolic fingerprint to specific metabolic processes. However, it
should be noted that these altered metabolites are at least partly reflected in CHF patients with
qi deficiency and blood stasis syndrome, which can be harnessed as markers of diseases for
personalized treatment based on TCM. Further mechanistic studies regarding this issue are
warranted.
4.2. Yang deficiency and water retention syndrome
Yang deficiency and water retention patients were observed to show higher levels of lactate,
gly-protein, pyruvic acid, alanine, glutamate, and lower levels of glucose, low-density
lipoprotein (LDL)/very low-density lipoprotein (VLDL), and high-density lipoprotein (HDL).
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Based on TCM theory, yang deficiency is associated with signs of chronic, weak, hypofunction,
hypometabolism, degenerative symptoms, and extremely common to be observed in late or
severe stage of many diseases [48]. The metabolism pattern in CHF patients with yang
deficiency and water retention syndrome demonstrated the decrease in glucose metabolism
and the increase in lactate, alanine, and pyruvate, suggesting that the disorder of carbohydrate
and energy metabolism in patients is more serious. There might be enhanced endogenous
glucose production from gluconeogenesis and pyruvic acid change may indicate increased
hepatic gluconeogenesis to provide extra pyruvate as a substrate for glucose [49]. That is why
syndrome typically occurs in patients with chronic heart failure at stage III and stage IV.
Moreover, increased glycoprotein indicates immune defects in the patients [50], while the
generally lower lipoprotein levels including LDL/VLDL and HDL also suggest the insufficient
absorption and utilization of protein in this phase. And higher excretion of measured metab-
olites (glutamate and alanine) could indicate that they might have more potential disturbance
of renal function, and resultant missed metabolites that are necessary for carbohydrate and
energy metabolism [51]. Previous study [52] investigated the urinary metabolites of syndrome
in patients with chronic kidney disease and revealed that the key distinguished metabolites
differed between yang deficiency and water retention syndrome and control group including
alanine, diethylamine, proline, and so on. As essential substance in cellular activities, the
deficiency will affect energy supply in all aspects of human body. Finally, these alterations are
likely important contributing factors to the altered metabolite profiling of CHF patients with
yang deficiency and water retention syndrome.
5. Conclusions and future perspectives
The future goals for metabolomics are the validation of existing biomarkers in terms of
mechanism and translation to man, together with a focus on characterizing the individual
health care. So far, metabolomics may be of special clinical relevance for the diagnosis of
syndromes of CHF and uncovering metabolomic pathway and prognosis in some extent,
which could lead to a better understanding and improvement of personalized interventions
for CHF. Metabolomics has also shown great advantage to discover possible early biomarkers
for the development of CHF and assess progression during treatment, which can aid the
discovery of prognostic indicators of outcome and disease response to personalized therapy.
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